These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 7543756)

  • 21. Screening for prostate cancer: a comparison of urologists and primary care physicians.
    McKnight JT; Tietze PH; Adcock BB; Maxwell AJ; Smith WO; Nagy MC
    South Med J; 1996 Sep; 89(9):885-8. PubMed ID: 8790311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of screening on prostate cancer rates and trends.
    Mettlin C
    Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
    Welch HG; Schwartz LM; Woloshin S
    J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minority issues in prostate disease.
    French DB; Jones LA
    Med Clin North Am; 2005 Jul; 89(4):805-16. PubMed ID: 15925651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Early detection of cancer of the prostate. Pros and cons].
    Hoesl CE; Altwein JE
    MMW Fortschr Med; 2005 Apr; 147(14):32, 34-6. PubMed ID: 15887681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
    Telesca D; Etzioni R; Gulati R
    Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prostate cancer screening].
    Villers A; Rébillard X; Soulié M; Davin JL; Coloby P; Moreau JL; Mejean A; Irani J; Coulange C; Mangin P;
    Prog Urol; 2003 Apr; 13(2):209-14. PubMed ID: 12765053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening for prostate cancer: current recommendations.
    Wilson SS; Crawford ED
    Urol Clin North Am; 2004 May; 31(2):219-26. PubMed ID: 15123402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What should men know about prostate-specific antigen screening before giving informed consent?
    Chan EC; Sulmasy DP
    Am J Med; 1998 Oct; 105(4):266-74. PubMed ID: 9809686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early detection of prostate cancer. Role of prostate-specific antigen.
    Prabhakaran VM
    Can Fam Physician; 1996 Apr; 42():709-12. PubMed ID: 8653039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
    Black A; Berg CD
    Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening and early detection for prostate cancer.
    Magoha GA
    East Afr Med J; 1997 Oct; 74(10):664-7. PubMed ID: 9529752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology and screening for prostate cancer.
    Moul JW
    Am J Manag Care; 1997 Aug; 3(8):1200-5; quiz 1208, 1210. PubMed ID: 10170302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive properties of serum-prostate-specific antigen testing in a community-based setting.
    Jacobsen SJ; Bergstralh EJ; Guess HA; Katusic SK; Klee GG; Oesterling JE; Lieber MM
    Arch Intern Med; 1996 Nov; 156(21):2462-8. PubMed ID: 8944739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of publication of US and European prostate cancer screening trials on PSA testing practices.
    Zeliadt SB; Hoffman RM; Etzioni R; Gore JL; Kessler LG; Lin DW
    J Natl Cancer Inst; 2011 Mar; 103(6):520-3. PubMed ID: 21357307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011.
    Nordström T; Aly M; Clements MS; Weibull CE; Adolfsson J; Grönberg H
    Eur Urol; 2013 Mar; 63(3):419-25. PubMed ID: 23083803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Focus on the screening for prostate cancer by PSA].
    Roumeguère T; Van Velthoven R
    Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attitudes and practices of primary care physicians for prostate cancer screening.
    Hoffman RM; Papenfuss MR; Buller DB; Moon TE
    Am J Prev Med; 1996; 12(4):277-81. PubMed ID: 8874692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.